These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16777416)

  • 1. Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners.
    Crooks PA; Kottayil SG; Al-Ghananeem AM; Byrn SR; Butterfield DA
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4291-5. PubMed ID: 16777416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors.
    Thompson CM; Wojno H; Greiner E; May EL; Rice KC; Selley DE
    J Pharmacol Exp Ther; 2004 Feb; 308(2):547-54. PubMed ID: 14600248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affinities of dihydrocodeine and its metabolites to opioid receptors.
    Schmidt H; Vormfelde Sv; Klinder K; Gundert-Remy U; Gleiter CH; Skopp G; Aderjan R; Fuhr U
    Pharmacol Toxicol; 2002 Aug; 91(2):57-63. PubMed ID: 12420793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Codeine analgesia is due to codeine-6-glucuronide, not morphine.
    Vree TB; van Dongen RT; Koopman-Kimenai PM
    Int J Clin Pract; 2000; 54(6):395-8. PubMed ID: 11092114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous determination of dihydrocodeine and dihydromorphine in serum by gas chromatography-tandem mass spectrometry.
    Hofmann U; Fromm MF; Johnson S; Mikus G
    J Chromatogr B Biomed Appl; 1995 Jan; 663(1):59-65. PubMed ID: 7704214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
    Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
    Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the mass spectrometric fragmentation of codeine and morphine after 13C-isotope biosynthetic labeling.
    Poeaknapo C; Fisinger U; Zenk MH; Schmidt J
    Phytochemistry; 2004 May; 65(10):1413-20. PubMed ID: 15231415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Derivatives of tramadol for increased duration of effect.
    Shao L; Abolin C; Hewitt MC; Koch P; Varney M
    Bioorg Med Chem Lett; 2006 Feb; 16(3):691-4. PubMed ID: 16257206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-inversion-associated conformational dynamics is unusually rapid in morphine alkaloids.
    Belostotskii AM; Goren Z; Gottlieb HE
    J Nat Prod; 2004 Nov; 67(11):1842-9. PubMed ID: 15568773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Opioid receptors and their selective ligands].
    Piestrzeniewicz MK; Fichna J; Janecka A
    Postepy Biochem; 2006; 52(3):313-9. PubMed ID: 17201067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [On the control of the morphine and the codeine contained in commercial preparations].
    GHIELMETTI G; MELA C
    Boll Chim Farm; 1960 Jul; 99():452-6. PubMed ID: 13704918
    [No Abstract]   [Full Text] [Related]  

  • 12. Enantioselective synthesis of (-)-dihydrocodeine and formal synthesis of (-)-thebaine, (-)-codeine, and (-)-morphine from a deprotonated α-aminonitrile.
    Geffe M; Opatz T
    Org Lett; 2014 Oct; 16(20):5282-5. PubMed ID: 25271381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II.
    Armstrong SC; Cozza KL
    Psychosomatics; 2003; 44(6):515-20. PubMed ID: 14597688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical characterization and regulation of endogenous morphine and codeine in the rat.
    Donnerer J; Cardinale G; Coffey J; Lisek CA; Jardine I; Spector S
    J Pharmacol Exp Ther; 1987 Aug; 242(2):583-7. PubMed ID: 3497260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of morphine enhancement of spontaneous seizure activity.
    Saboory E; Derchansky M; Ismaili M; Jahromi SS; Brull R; Carlen PL; El Beheiry H
    Anesth Analg; 2007 Dec; 105(6):1729-35, table of contents. PubMed ID: 18042875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of opioids on compound action potentials in frog sciatic nerves and their chemical structures.
    Mizuta K; Fujita T; Nakatsuka T; Kumamoto E
    Life Sci; 2008 Aug; 83(5-6):198-207. PubMed ID: 18593589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous morphine: a role in wellness medicine.
    Stefano GB
    Med Sci Monit; 2004 Jun; 10(6):ED5. PubMed ID: 15173675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: Potential therapeutic efficacy against morphine dependence.
    Deb I; Paira P; Hazra A; Banerjee S; Dutta PK; Mondal NB; Das S
    Bioorg Med Chem; 2009 Aug; 17(16):5782-90. PubMed ID: 19640720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
    Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
    J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.